EMA: disclosure policy ‘will not impinge IP rights’
This article was originally published in Scrip
The European Medicines Agency’s new policy on clinical trial data disclosure will ensure transparency in the interests of public health without impinging on the company’s intellectual property rights. So says the agency in publishing the final advice from its five cross-sector groups that have been looking at the scientific, technical, legal and ethical issues surrounding this vexed and controversial topic.
You may also be interested in...
The bedding-in period is ending for Europe’s one-year-old system for preventing the circulation of fake medicines, and the scheme is gearing up for a more fully operational stage.
EU and US regulators have opposing views when it comes to Merck's applications for a new indication and new dosing schedule for the company's successful PD-1 inhibitor Keytruda.
Regulators have pulled out all the stops in their efforts to get the Ebola vaccine to the marketing authorization stage in Africa.